Project description:Extensive high-throughput sequencing led to the characterization of four main medulloblastoma subgroups. However, to date these analyses have not attained a global comprehension of their dynamic network complexity. Wishing to get a comprehensive view of all medulloblastoma subgroups, we employed a proteomic analysis to integrate accurate protein activity. In this study we present the first analysis regrouping genomic and methylation status, whole-transcriptome sequencing and quantitative proteomics. First, our proteomic analysis clarified medulloblastoma subgroup identity. Second, analysis of proteome and phosphoproteome highlighted disregulated signalling pathways that have not been predicted by transcriptomic analysis. Altogether, combined multi-scale analyses of medulloblastoma have allowed us to identify and prioritize novel molecular drivers involved in human medulloblastoma.

2018-09-09 | GSE107508 | GEO

Proteogenomic landscape of medulloblastoma subgroups [methylation]

2018-09-09 | GSE104728 | GEO

Proteogenomic Analysis of Medulloblastoma [methylation array]

Project description:These methylation arrays were performed as part of a project aiming to integrate quantitative proteomic, gene expression and epigenetic data from the childhood brain tumor medulloblastoma.

2018-06-14 | GSE109402 | GEO

Integrated proteogenomic analysis of medulloblastoma progression (DNA methylation)

Project description:Medulloblastoma is a malignant pediatric brain cancer, whose primary tumors are representatively classified into four molecular subgroups, WNT, SHH, Group 3 and 4. Although the molecular characters have been known well, conventional chemotherapy and radiotherapy after surgery have been used for the treatment to young children, which cause harmful side effects to their chronic health conditions. Moreover, the patients frequently suffer from recurrence and have shown poor prognosis following relapse. Here, we characterized the five layers of molecular profiles and identified potential therapeutic targets of medulloblastoma by performing multi-omics-based analysis including mass spectrometric proteome analysis. The proteome-added integrated analyses characterized new subtypes which showed specific protein functions, such as cell cycle (SHHa), EMT (G4a) and neuronal (G4b and SHHb) functions. Based on the kinase-substrate relations of phospho-proteome, we found the kinase-centered functional modularity of each subtype. These features were significantly associated with clinical features, such as recurrence and progression, and informed us the therapeutic options. Thus, we suggest that our data and analysis would support molecular basis and clinically applicable targets for precision diagnostics and therapeutics of medulloblastoma.

2023-07-31 | GSE209668 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data